Impact
Hadean Ventures has a strong commitment to being a driver for positive changes in the society as a whole.
At Hadean Ventures, impact starts with the science. We invest in companies developing products with the potential to address unmet medical needs — and support them with capital, deep sector expertise, strong networks and active ownership.
Our role goes beyond funding. We work closely with management teams to help translate research into clinical and commercial progress, with the aim of supporting better outcomes for patients and society.
Abliva is a strong example of how specialist venture capital can help advance Nordic science toward global impact. Hadean backed the company from 2020 and supported its development through active board work, helping drive strategic progress, regulatory milestones and clinical momentum in primary mitochondrial disease.
Abliva's lead asset, KL1333, is being developed for patients with mitochondrial DNA-driven primary mitochondrial diseases, where treatment options remain limited. Following positive clinical progress, Pharming completed its acquisition of Abliva in 2025.
Saga Diagnostics demonstrates the impact potential of precision diagnostics. The company has developed Pathlight™, a tumor-informed molecular residual disease platform designed to detect and monitor cancer recurrence with high sensitivity. Hadean backed the company from 2019 and supported its development through active board participation and strategic support until its commercial entry in 2025.
In 2026, Roche / Foundation Medicine completed its acquisition of Saga Diagnostics, with Pathlight strengthening Foundation Medicine's monitoring portfolio and supporting treatment response and recurrence monitoring.
How we create value
Our impact & ESG pillarsUnmet Medical Need
We back companies developing new therapies, diagnostics and technologies for areas of significant unmet medical need, contributing to better health and wellbeing.
Active Ownership
We actively contribute at board level, bringing strong scientific and operational expertise, as well as networks, to advance research, development, and innovation toward successful market approval.
ESG Integration
We integrate ESG throughout our investment process and portfolio support, with a focus on good governance, environmental awareness and gender equality and inclusion.
The UN Sustainability Goals we contribute to:
The launch of the UN Sustainable Development Goals (SDGs) in 2015 made clear that the global community of countries relies heavily on the private sector to solve some of the most urgent problems the world is facing, and further following the launch of the SFDR in the EU/EEA by making financial market participants contribute to sustainable investments through their business activities, asset allocation and investment decisions (UNPRI).
Illustrative layout for discussion. Webpage copy should be reviewed against final transaction status and legal/ compliance requirements before publication.